Stapokibart improves sleep domain scores in patients with chronic rhinosinusitis with nasal polyps
In a post-hoc analysis of the phase 3 CROWNS-2 study, stapokibart significantly improved SNOT-22 Sleep domain scores compared to placebo during the 24-week double-blind period. These improvements were maintained or further improved during the 28-week open-label extension and 8-week safety follow-up.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Stapokibart improves sleep domain scores in patients with chronic rhinosinusitis with nasal polyps The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Stapokibart improves sleep domain scores in patients with chronic rhinosinusitis with nasal polyps
This conclusion is most relevant to: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]. (Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026) —
How It Works
The proposed biological pathway:
- ▸Stapokibart binds to IL-4 receptor α subunit
- ▸Blocks IL-4 and IL-13 signaling pathways
- ▸Reduces type 2 inflammation in nasal and sinus mucosa
- ▸Improves sinonasal symptoms including sleep disturbance
Who Might Benefit
Evidence fit by population:
- ▸Patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
Recommended Dose
300 mg every 2 weeks
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Post-hoc analysis, not pre-specified primary endpoint
- ▸Specific effect sizes and p-values for sleep domain not reported in abstract
Frequently Asked Questions
What is stapokibart?▼
Stapokibart is an anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody that blocks IL-4 and IL-13 signaling pathways.
How was sleep measured in this study?▼
Sleep was assessed using the Sleep domain of the 22-item sinonasal outcome test (SNOT-22), a validated patient-reported outcome measure.
How long did the sleep improvements last?▼
Improvements in sleep domain scores were maintained during the 28-week open-label extension and 8-week safety follow-up period.
What other quality of life domains improved?▼
Stapokibart also significantly improved Nasal, Ear/facial, and Emotion domain scores of the SNOT-22.
References
- 1.Yan B, Jin Z, Zhang L, Wang C. “[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]..” Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026. PMID: 42402685 DOI: 10.13201/j.issn.2096-7993.2026.07.010